Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary ... of unique prescribers, new patient prescriptions, refill ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year, up 15%. COPD could open up a massive new market for the drug, which still has ...

Global health projections indicate that COPD will affect approximately 600 ... a crucial role in protecting lung function, offering a new perspective on their therapeutic potential beyond diabetes ...

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

A new study has found that people ... and so it is not yet clear if the effect of the drug had to do with the weight loss and its effect on COPD, or it had a different mechanism of action.

A new and interesting finding was that having a history of gastroesophageal reflux disease (GERD) or heartburn seems to correlate with the development of COPD exacerbations, [20] a factor that was ...

More information: Avik Ray et al, Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes, JAMA Internal Medicine (2025).DOI ...